Key result
TAVI shows similar 2-year mortality compared with SAVR in bicuspid aortic valve and heart failure.
Why the study?
Does transcatheter aortic valve implantation (TAVI) compared with surgical aortic valve replacement (SAVR) affect 2-year all-cause mortality in adults with bicuspid aortic valve and heart failure?
Cohort (n=766)
Yes
Does transcatheter aortic valve implantation (TAVI) compared with surgical aortic valve replacement (SAVR) affect 2-year all-cause mortality in adults with bicuspid aortic valve and heart failure?
Answers are grounded in this paper and cite their sources.
In propensity-matched adults with bicuspid aortic valve and heart failure, 2-year mortality and secondary cardiovascular outcomes did not differ significantly between TAVI and SAVR, though wide confidence intervals could not rule out clinically important harm with TAVI.
BACKGROUND: The optimal valve replacement strategy for adults with bicuspid aortic valve (BAV) and heart failure remains uncertain. We compared outcomes after transcatheter aortic valve implantation (TAVI) versus surgical aortic valve replacement (SAVR). METHODS: Using the TriNetX Global Collaborative Network, we identified adults with BAV and heart failure diagnoses during 2020-2024 who underwent TAVI or SAVR. Patients with endocarditis, heart transplant, ventricular assist devices, concomitant non-aortic valve surgery, or coronary artery bypass grafting were excluded. Propensity score matching incorporated demographics, comorbidities, medications, and clinical measurements. All-cause mortality was the primary outcome; secondary outcomes included acute myocardial infarction, ischemic stroke, and all-cause hospitalization. Outcomes were assessed over 2 years using Kaplan-Meier and Cox proportional hazards analyses. Hernia and upper respiratory infection served as prespecified falsification endpoints. RESULTS: Propensity score matching yielded 383 patients per group, with a mean age of 65.7 years. Mortality occurred in 22 TAVI patients (5.7%) and 14 SAVR patients (3.7%; HR 1.57, 95% CI 0.80-3.07). No statistically significant differences were detected in mortality, acute myocardial infarction (HR 1.34, 95% CI 0.84-2.14), ischemic stroke (HR 1.11, 95% CI 0.67-1.83), or all-cause hospitalization (HR 0.93, 95% CI 0.79-1.10). Falsification endpoints did not differ significantly. Left ventricular ejection fraction was recorded in 27.4% of matched TAVI patients and 26.4% of matched SAVR patients. CONCLUSION: The imprecise mortality estimate did not exclude clinically important harm associated with TAVI. These observational findings are hypothesis-generating and do not establish equivalence or noninferiority.
No takes yet. Share an insight, caveat, or question.
Mortada et al. (2026) conducted a cohort in Bicuspid aortic valve and heart failure (n=766). Transcatheter aortic valve implantation (TAVI) vs. Surgical aortic valve replacement (SAVR) was evaluated on All-cause mortality (HR 1.57, 95% CI 0.80-3.07). TAVI vs SAVR in adults with bicuspid aortic valve and heart failure showed no significant difference in 2-year mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: